BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lam A, Yoshida EJ, Bui K, Katrivesis J, Fernando D, Nelson K, Abi-jaoudeh N. Demographic and facility volume related outcomes in radiofrequency ablation for early-stage hepatocellular carcinoma. HPB 2019;21:849-56. [DOI: 10.1016/j.hpb.2018.10.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Harada D, Takigawa N. Oligoprogression in Non-Small Cell Lung Cancer. Cancers (Basel) 2021;13:5823. [PMID: 34830977 DOI: 10.3390/cancers13225823] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Jairam V, Park HS, Decker RH. Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer. Cancer J 2020;26:129-36. [PMID: 32205537 DOI: 10.1097/PPO.0000000000000433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Kwon J, Chun KS, Song IS, Kim SH, Han S. Long-term outcome of intraoperative radiofrequency ablation for hepatocellular carcinoma and its efficacy as a primary treatment. Ann Hepatobiliary Pancreat Surg 2020;24:24-32. [PMID: 32181425 DOI: 10.14701/ahbps.2020.24.1.24] [Cited by in F6Publishing: 1] [Reference Citation Analysis]